Fox News
US · 2 hrs ago
AI scored
Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
78Accuracy
centreBias
0Ratings
💬 0Comments
AI Analysis
Accuracy 78/100
Partisan intensity 15/100
ObjectivePartisan
Centre / Neutral ✓ Fair headline
A clinical trial for bowel cancer treatment using pembrolizumab immunotherapy before surgery has shown all participants remaining cancer-free at nearly the three-year mark.
Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!